Univariate analysis for factors associated with risk of R/R disease after CD19 CAR T-cell therapy
| . | Univariate analysis . | |
|---|---|---|
| Parameter . | HR (95% CI) . | P . |
| Age (>40 y vs ≤40 y) | 1.11 (0.58-2.10) | .8 |
| Sex (male vs female) | 0.75 (0.37-1.55) | .5 |
| Prior lines of treatment before CAR T cells (>3 vs ≤3) | 1.55 (0.81-2.95) | .2 |
| Philadelphia chromosome–positive ALL (yes vs no) | 1.06 (0.54-2.07) | .9 |
| Prior HSCT before CAR T cells (yes vs no) | 1.43 (0.75-2.71) | .3 |
| Prior blinatumomab before CAR T cells (yes vs no) | 1.09 (0.53-2.25) | .8 |
| Prior inotuzumab ozogamicin before CAR T cells (yes vs no) | 0.93 (0.28-3.05) | .9 |
| Bridging therapy before CAR T cells (no or nonintensive vs intensive therapy) | 1.32 (0.64-2.71) | .4 |
| Baseline LDH before lymphodepletion (normal vs high) | 0.93 (0.48-1.83) | .8 |
| Baseline platelet count before lymphodepletion (normal vs low) | 0.73 (0.37-1.43) | .4 |
| Disease status before lymphodepletion (morphologic vs MRD) | 2.20 (1.09-4.41) | .02 |
| Lymphodepletion chemotherapy (fludarabine-containing regimen vs cyclophosphamide) | 1.05 (0.67-1.65) | .8 |
| CRS (yes vs no) | 0.73 (0.30-1.75) | .5 |
| ICANS (yes vs no) | 0.63 (0.33-1.20) | .2 |
| Steroid exposure during CAR T-cell therapy (yes vs no) | 0.98 (0.49-1.95) | .9 |
| Tocilizumab exposure during CAR T-cell therapy (yes vs no) | 1.35 (0.70-2.60) | .4 |
| Duration of steroid exposure (d) | 0.95 (0.83-1.08) | .4 |
| Steroid dose intensity during CAR T-cell therapy (mg/kg/d) | 0.77 (0.20-3.03) | .7 |
| HSCT consolidation after CAR T-cell therapy | 0.55 (0.23-1.32) | .2 |
| . | Univariate analysis . | |
|---|---|---|
| Parameter . | HR (95% CI) . | P . |
| Age (>40 y vs ≤40 y) | 1.11 (0.58-2.10) | .8 |
| Sex (male vs female) | 0.75 (0.37-1.55) | .5 |
| Prior lines of treatment before CAR T cells (>3 vs ≤3) | 1.55 (0.81-2.95) | .2 |
| Philadelphia chromosome–positive ALL (yes vs no) | 1.06 (0.54-2.07) | .9 |
| Prior HSCT before CAR T cells (yes vs no) | 1.43 (0.75-2.71) | .3 |
| Prior blinatumomab before CAR T cells (yes vs no) | 1.09 (0.53-2.25) | .8 |
| Prior inotuzumab ozogamicin before CAR T cells (yes vs no) | 0.93 (0.28-3.05) | .9 |
| Bridging therapy before CAR T cells (no or nonintensive vs intensive therapy) | 1.32 (0.64-2.71) | .4 |
| Baseline LDH before lymphodepletion (normal vs high) | 0.93 (0.48-1.83) | .8 |
| Baseline platelet count before lymphodepletion (normal vs low) | 0.73 (0.37-1.43) | .4 |
| Disease status before lymphodepletion (morphologic vs MRD) | 2.20 (1.09-4.41) | .02 |
| Lymphodepletion chemotherapy (fludarabine-containing regimen vs cyclophosphamide) | 1.05 (0.67-1.65) | .8 |
| CRS (yes vs no) | 0.73 (0.30-1.75) | .5 |
| ICANS (yes vs no) | 0.63 (0.33-1.20) | .2 |
| Steroid exposure during CAR T-cell therapy (yes vs no) | 0.98 (0.49-1.95) | .9 |
| Tocilizumab exposure during CAR T-cell therapy (yes vs no) | 1.35 (0.70-2.60) | .4 |
| Duration of steroid exposure (d) | 0.95 (0.83-1.08) | .4 |
| Steroid dose intensity during CAR T-cell therapy (mg/kg/d) | 0.77 (0.20-3.03) | .7 |
| HSCT consolidation after CAR T-cell therapy | 0.55 (0.23-1.32) | .2 |
LDH, lactate dehydrogenase.